The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator ...

Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

Sangamo Therapeutics (SGMO) stock plunged as Pfizer (PFE) ends collaboration on hemophilia A gene therapy. Find out the ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

Sangamo Therapeutics Inc.’s stock tumbled 56% on Tuesday for its second-biggest one-day percentage decline ever, after Pfizer ...

Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration ...

Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...

We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a ...

Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments ...